BioTech/Drugs - San Diego, CA, US
Respivant Sciences, a subsidiary of Roivant Sciences, is global, clinical-stage biopharmaceutical company dedicated to developing new therapies for patients with respiratory diseases.The company's lead candidate, RVT-1601, is currently being evaluated in the SCENIC study for people with idiopathic pulmonary fibrosis (IPF), a progressive lung disease characterized by scarring of the lung for unknown reasons, to assess the potential of a new inhaled therapy to significantly reduce cough and improve quality of life. RVT-1601 is an inhaled non-steroidal, anti-inflammatory drug delivered directly to the lungs via a hand-held, silent, electronic nebulizer. Learn more at https://www.respivant.com.
Outlook
Dyn Managed DNS
Microsoft Office 365
Google Cloud Hosting